Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

Donald E. Kohan¹, Paola Fioretto², Weihua Tang³ and James F. List³

¹Division of Nephrology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA; ²Department of Medicine, University of Padua, Padua, Italy and ³Research and Development, Bristol-Myers Squibb, Princeton, New Jersey, USA

In patients with diabetes, glycemic improvement by sodium-glucose cotransporter-2 inhibition depends on the kidney’s ability to filter glucose. Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces hyperglycemia in patients with diabetes and normal or mildly impaired renal function. In this randomized, double-blind, placebo-controlled study we assessed daily treatment with dapagliflozin in 252 patients with inadequately controlled type 2 diabetes and moderate renal impairment. The primary endpoint, the mean change in HbA1c, was not statistically different from placebo after 24 weeks (−0.41% and −0.44% for 5- and 10-mg doses, respectively, and −0.32% for placebo). The mean weight change from baseline was −1.54 and −1.89 kg for the 5- and 10-mg doses, respectively, and +0.21 kg for placebo. The mean systolic and diastolic blood pressure decreased in the dapagliflozin groups compared to placebo. Through 104 weeks, 13 patients receiving dapagliflozin and no patients receiving placebo experienced bone fracture. At 1 week, the mean serum creatinine increased with dapagliflozin 5 mg (+0.13 mg/dl) and 10 mg (+0.18 mg/dl) and did not change further after 104 weeks. Mean serum electrolytes did not change in any group, and there were fewer episodes of hyperkalemia with dapagliflozin than placebo. Thus, in patients with moderate renal impairment, dapagliflozin did not improve glycemic control, but reduced weight and blood pressure.

Kidney International (2014) 85, 962–971; doi:10.1038/ki.2013.356; published online 25 September 2013
KEYWORDS: diabetes mellitus; renal function

Correspondence: Donald E. Kohan, Division of Nephrology, University of Utah Health Sciences Center, 1900 East, 30 North, Salt Lake City, Utah 84132, USA. E-mail: donald.kohan@hsc.utah.edu

Received 25 April 2013; revised 24 June 2013; accepted 18 July 2013; published online 25 September 2013
Groups generally appeared to be balanced with respect to key demographic and baseline characteristics (Table 1).

**Efficacy**
In this moderate renal impairment population, the primary end point, mean change in hemoglobin A1c (HbA1c; % (s.e)) excluding data after glycemic rescue, was not statistically different from placebo at week 24 (–0.32 (0.17), –0.41 (0.17), and –0.44 (0.17) for placebo, 5 and 10-mg dapagliflozin, respectively, and \( P = 0.561 \) and \( P = 0.435 \) for dapagliflozin 5 and 10 mg vs. placebo, respectively; Table 2). Changes in HbA1c at 52 and at 104 weeks are shown in

---

**Figure 1 | Trial profile through 104 weeks.** A total of five patients left the trial because they ‘no longer met study criteria.’ For the three patients in the placebo group, (1) the patient had insulin regimen altered, which is against the protocol guidance, (2) the patient met discontinuation criteria for sustained elevated serum creatinine, and (3) the patient was inappropriately randomized with a high screening potassium and removed a few days after starting treatment. The patient in the 5-mg group had myasthenia gravis, was administered prednisone for treatment and was asked to be discontinued by the medical monitor. The patient in the 10-mg group was discontinued owing to serum creatinine greater than two times the baseline at day 78.
Fasting plasma glucose (FPG) showed larger mean reductions for dapagliflozin 5 and 10 mg compared with placebo at 24 weeks (Table 2) and over 104 weeks (Table 3). Similar results for HbA1c and FPG were obtained in analyses that include data after glycemic rescue. Similar results for HbA1c and FPG were obtained in analyses that include data after glycemic rescue.

Table 3. Fasting plasma glucose (FPG) showed larger mean reductions for dapagliflozin 5 and 10 mg compared with placebo at 24 weeks (Table 2) and over 104 weeks (Table 3). Similar results for HbA1c and FPG were obtained in analyses that include data after glycemic rescue. There was an increase in the 24-h urine glucose/creatinine ratio with dapagliflozin compared with placebo (Table 3; Figure 2). The dapagliflozin groups experienced mean weight loss, whereas there was an increase in the placebo group (Figure 2 and Table 3).

Post-hoc analysis by baseline chronic kidney disease (CKD) stage (Table 4) showed a larger reduction in adjusted mean change in HbA1c and FPG from baseline to week 24 for dapagliflozin vs. placebo for stage 3A CKD (estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 ml/min per 1.73 m²) than for stage 3B CKD (eGFR ≥ 30 and < 45 ml/min per 1.73 m²). The placebo-corrected mean reduction from baseline in HbA1c at week 24 for dapagliflozin treatment groups in patients in stage 3A ranges between 0.33 and 0.37, whereas there is no change observed in patients in stage 3B. No difference was observed for change in body weight at week 24 between stages 3A and 3B (Table 4).

Safety

The proportions of patients experiencing an adverse event were similar for dapagliflozin and placebo (Table 5). More patients in the placebo group had adverse events leading to discontinuation (Table 5) than in dapagliflozin groups. Ten deaths were reported during the 104 weeks of treatment: 5 in placebo (1—traumatic brain injury, 2—acute myocardial infarction, 1—acute cardiac failure, myocardial infarction, and renal failure, and 1—general physical health deterioration), 2 in dapagliflozin 5 mg (both with myocardial infarction), and 3 in dapagliflozin 10 mg (1 each—myocardial infarction, cardiac failure, and sepsis). The proportions of patients with serious adverse events through the 104-week treatment period were similar for dapagliflozin and placebo. A higher incidence of genital infections was reported with dapagliflozin than placebo, and a similar incidence of patients experienced urinary tract infections with dapagliflozin and placebo (Table 5).

Through 104 weeks, 13 (9.7%) patients experienced fracture in the dapagliflozin groups (5 at 5 mg and 8 at 10 mg) vs. 0 on placebo (Table 5). All fractures occurred after trauma and were mostly of low impact. Two of 13 fractures were assessed as serious adverse events (1 hip and 1 elbow, both with dapagliflozin 10 mg). None of these events led to discontinuation of study medication. Seven of 13 patients who sustained fracture had a history of diabetic neuropathy or exhibited orthostatic hypotension. Of the 13 patients reporting fracture, 5 had stage 3A CKD and 8 had stage 3B CKD.

Events of renal impairment or renal failure were uncommon during the 104-week period (Table 5). Reports of volume depletion events were more frequent in the dapagliflozin groups than in the placebo group (Table 5).
patients (two on dapagliflozin 10 mg and four on placebo) experienced major episodes of hypoglycemia through the 104 weeks (Table 5).

**Blood pressure**

At week 1, there were mean reductions from baseline in seated systolic and diastolic blood pressure (−6.83 and −2.53 mm Hg, respectively) for dapagliflozin 10 mg. The magnitude of the mean reductions was generally stable for the first 52 weeks for this treatment group (−6.73 and −2.91 mm Hg, respectively). These reductions lessened somewhat after week 52 (Table 6). Although the proportion of patients with measured orthostatic hypotension at any assessment time during the 104 weeks was higher for the dapagliflozin groups (7.8% to 15.6%) than for the placebo group (2.9% to 10.5%), this difference appears to reflect a higher rate of orthostatic hypotension seen in dapagliflozin at baseline (14.5% and 14.1% for the dapagliflozin 5- and 10-mg groups, respectively, vs. 7.1% for placebo).

| Table 3 | Change from baseline in efficacy and renal parametersa |
|---------|-----------------------------------------------------|
|                     | Placebo (n = 84) | Dapagliflozin 5 mg (n = 83) | Dapagliflozin 10 mg (n = 85) |
|                     | n | Value | n | Value | n | Value |
| HbA1c (%)b,c |     |       |     |       |     |       |
| Baseline       | 84 | 8.53 (1.28) | 83 | 8.30 (1.04) | 83 | 8.23 (0.98) |
| Change at week 24 | 50 | −0.28 [0.13] | 63 | −0.38 [0.13] | 65 | −0.41 [0.13] |
| Change at week 52 | 13 | −0.06 [0.18] | 30 | −0.34 [0.16] | 35 | −0.34 [0.16] |
| Change at week 104 | 4 | −0.67 [0.41] | 8 | −1.21 [0.38] | 10 | −0.75 [0.22] |
| FPG (mg/dlb,c |     |       |     |       |     |       |
| Baseline       | 84 | 150 (48) | 83 | 161 (56) | 84 | 165 (67) |
| Change at week 24 | 50 | 2.53 [6.86] | 60 | −9.5 [6.35] | 65 | −9.29 [6.24] |
| Change at week 52 | 13 | −8.58 [9.00] | 29 | −14.98 [6.78] | 33 | −16.49 [6.54] |
| Change at week 104 | 4 | −18.25 [36.62] | 8 | −31.00 [13.55] | 10 | −22.10 [8.22] |
| 24-H urinary glucose:creatinine ratio (g/g)c |     |       |     |       |     |       |
| Baseline       | 84 | 7.19 (23.15) | 72 | 3.16 (7.08) | 68 | 5.43 (12.75) |
| Change at week 6 | 63 | −2.20 (23.40) | 69 | 24.39 (18.75) | 63 | 24.78 (16.46) |
| Change at week 52 | 34 | −5.01 (25.07) | 40 | 26.84 (15.37) | 38 | 21.74 (17.47) |
| Change at week 104 | 36 | −4.81 (30.03) | 33 | 26.24 (14.60) | 38 | 21.97 (20.08) |
| Weight (kg)d |     |       |     |       |     |       |
| Baseline       | 84 | 89.6 (20.1) | 83 | 95.2 (20.9) | 85 | 93.3 (17.3) |
| Change at week 24 | 63 | 0.68 [0.45] | 70 | −1.34 [0.43] | 69 | −1.72 [0.44] |
| Change at week 52 | 51 | 1.10 [0.60] | 64 | −1.17 [0.55] | 64 | −1.75 [0.56] |
| Change at week 104 | 42 | 2.63 [0.79] | 41 | −0.34 [0.75] | 51 | −1.10 [0.74] |
| eGFR (ml/min per 1.73 m²)b |     |       |     |       |     |       |
| Baseline       | 84 | 45.6 (10.0) | 83 | 44.2 (8.8) | 85 | 43.9 (10.6) |
| Change at week 24 | 62 | −0.25 [0.92] | 70 | −2.38 [0.84] | 69 | −4.80 [0.82] |
| Change at week 52 | 49 | −2.58 [1.16] | 64 | −2.08 [0.99] | 63 | −4.46 [0.97] |
| Change at week 104 | 42 | −2.38 [1.01] | 40 | −1.71 [1.23] | 50 | −3.50 [1.02] |
| CrCl (ml/min) |     |       |     |       |     |       |
| Baseline       | 84 | 60.4 (17.3) | 83 | 62.3 (17.3) | 85 | 59.9 (17.8) |
| Change at week 24 | 62 | 0.03 [1.11] | 69 | −4.02 [1.10] | 69 | −7.38 [0.97] |
| Change at week 52 | 49 | −2.56 [1.31] | 64 | −4.15 [1.13] | 63 | −7.27 [1.23] |
| Change at week 104 | 42 | −2.35 [1.27] | 40 | −3.30 [1.69] | 50 | −6.32 [1.22] |

Abbreviations: CrCl, creatinine clearance; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c.

aData are mean (s.d.) or mean [s.e.].

bUsed longitudinal repeated-measure analysis excluding data after rescue.

cUsed descriptive statistics including data after rescue.

dUsed longitudinal repeated-measure analysis including data after rescue.

Laboratory parameters with abnormalities

A mean increase from baseline in serum creatinine was observed at week 1 in dapagliflozin 5 mg (0.13 mg/dl) and 10 mg (0.18 mg/dl). The magnitude of this mean increase remained unchanged throughout the remainder of the study for dapagliflozin (Table 6). A similar pattern was seen for eGFR and creatinine clearance, with early mean decreases at week 1 followed by longer-term stability (Table 3 and Figure 3). Mean changes in eGFR through week 104 did not appear to differ for CKD stage 3A or stage 3B patients. The proportion of patients with a marked abnormality in serum creatinine (defined as a value ≥ 2.5 or ≥ 1.5 mg/dl increase from baseline) through 104 weeks of treatment was similar across the treatment groups. Over time, mean urinary albumin:creatinine and urinary protein:creatinine ratios fluctuated in all groups. Values of urinary albumin:creatinine ratio > 1800 mg/g during the 104-week treatment period were reported in a higher proportion of patients in placebo (13.3%) than in dapagliflozin 5 or 10 mg (10.8% and 9.5%, respectively). In shift analyses, urinary albumin:creatinine
ratio was characterized as belonging to one of three prespecified categories: 0 to <30 mg/g (normoalbuminuria), 30 to <300 mg/g (microalbuminuria), or ≥300 mg/g (macroalbuminuria), and showed that for dapagliflozin-treated patients, relative to baseline, 38 patients shifted to a lower category at week 104 (18 patients from microalbuminuria to normoalbuminuria, 19 from macroalbuminuria to microalbuminuria, and 1 from macroalbuminuria to normoalbuminuria) compared with 18 patients who shifted to a higher category (12 patients from normoalbuminuria to microalbuminuria and 6 from microalbuminuria to macroalbuminuria). In the placebo group, the number of patients who shifted to a lower category (nine patients, five from microalbuminuria to normoalbuminuria and four from macroalbuminuria to microalbuminuria) was similar to the number of patients who shifted to a higher category (12 patients, 3 from normoalbuminuria to microalbuminuria and 9 from microalbuminuria to macroalbuminuria). For one
No change from baseline was noted in mean serum sodium, potassium, bicarbonate, chloride, or calcium with dapagliflozin or placebo. No evidence of hyponatremia or hypokalemia was observed. Marked abnormalities of elevated potassium (≥6 mEq/l) were more common in the placebo group (12.0%) than in dapagliflozin 5-mg (4.8%) or 10-mg groups (4.8%) during the study. More patients experienced marked abnormalities of hyperphosphatemia (≥5.6 mg/dl for patients 17 to 65 years of age or ≥5.1 mg/dl for patients ≥66 years of age) on treatment with dapagliflozin 5 mg (15.7%) or 10 mg (14.3%) than placebo (8.4%). Patients receiving dapagliflozin had a larger mean decrease in serum uric acid than those receiving placebo (Table 6). The mean concentration of serum parathyroid hormone exceeded the upper limit of normal at baseline in all treatment groups, and there were larger mean increases in parathyroid hormone in dapagliflozin compared with placebo during the cumulative 104-week period (Table 6).

**DISCUSSION**

Dapagliflozin's ability to inhibit renal glucose reabsorption declines with decreasing GFR. Urinary glucose excretion is about 50% lower in patients with T2DM treated with dapagliflozin having CKD stage 3, as compared with patients with normal or mildly impaired renal function.11 Such GFR dependence is expected given the fall in filtered glucose load with worsening CKD stage. Consistent with the lower pharmacodynamic activity, dapagliflozin did not have a significant impact on glycemic control in patients with more advanced CKD, although there was a modest decrease in HbA1c and FPG in patients with a GFR of 45–59 ml/min.

Dapagliflozin showed improvements in weight despite lacking glycemic efficacy. Patients receiving dapagliflozin had modest weight loss in contrast to those receiving placebo, who had small weight gain. The placebo-subtracted weight changes observed here are similar to other studies in patients with normal to mildly impaired renal function,4–9 and the weight loss in this study was similar between patients in CKD stages 3A and 3B. The apparent incongruity in glycemic and weight outcomes may be due to a variety of factors. Patients in this study may have already reached a threshold of glucosuria, beyond which further weight loss was not achieved because of compensatory mechanisms to defend patient each in the dapagliflozin groups and the placebo group, the shift was not reported, and the remaining patients did not exhibit a shift from baseline at week 104.

No change from baseline was noted in mean serum sodium, potassium, bicarbonate, chloride, or calcium with dapagliflozin or placebo. No evidence of hyponatremia or hypokalemia was observed. Marked abnormalities of elevated potassium (≥6 mEq/l) were more common in the placebo group (12.0%) than in dapagliflozin 5-mg (4.8%) or 10-mg groups (4.8%) during the study. More patients experienced marked abnormalities of hyperphosphatemia (≥5.6 mg/dl for patients 17 to 65 years of age or ≥5.1 mg/dl for patients ≥66 years of age) on treatment with dapagliflozin 5 mg (15.7%) or 10 mg (14.3%) than placebo (8.4%). Patients receiving dapagliflozin had a larger mean decrease in serum uric acid than those receiving placebo (Table 6). The mean concentration of serum parathyroid hormone exceeded the upper limit of normal at baseline in all treatment groups, and there were larger mean increases in parathyroid hormone in dapagliflozin compared with placebo during the cumulative 104-week period (Table 6).

**DISCUSSION**

Dapagliflozin's ability to inhibit renal glucose reabsorption declines with decreasing GFR. Urinary glucose excretion is about 50% lower in patients with T2DM treated with dapagliflozin having CKD stage 3, as compared with patients with normal or mildly impaired renal function.11 Such GFR dependence is expected given the fall in filtered glucose load with worsening CKD stage. Consistent with the lower pharmacodynamic activity, dapagliflozin did not have a significant impact on glycemic control in patients with more advanced CKD, although there was a modest decrease in HbA1c and FPG in patients with a GFR of 45–59 ml/min.

Dapagliflozin showed improvements in weight despite lacking glycemic efficacy. Patients receiving dapagliflozin had modest weight loss in contrast to those receiving placebo, who had small weight gain. The placebo-subtracted weight changes observed here are similar to other studies in patients with normal to mildly impaired renal function,4–9 and the weight loss in this study was similar between patients in CKD stages 3A and 3B. The apparent incongruity in glycemic and weight outcomes may be due to a variety of factors. Patients in this study may have already reached a threshold of glucosuria, beyond which further weight loss was not achieved because of compensatory mechanisms to defend patient each in the dapagliflozin groups and the placebo group, the shift was not reported, and the remaining patients did not exhibit a shift from baseline at week 104.

No change from baseline was noted in mean serum sodium, potassium, bicarbonate, chloride, or calcium with dapagliflozin or placebo. No evidence of hyponatremia or hypokalemia was observed. Marked abnormalities of elevated potassium (≥6 mEq/l) were more common in the placebo group (12.0%) than in dapagliflozin 5-mg (4.8%) or 10-mg groups (4.8%) during the study. More patients experienced marked abnormalities of hyperphosphatemia (≥5.6 mg/dl for patients 17 to 65 years of age or ≥5.1 mg/dl for patients ≥66 years of age) on treatment with dapagliflozin 5 mg (15.7%) or 10 mg (14.3%) than placebo (8.4%). Patients receiving dapagliflozin had a larger mean decrease in serum uric acid than those receiving placebo (Table 6). The mean concentration of serum parathyroid hormone exceeded the upper limit of normal at baseline in all treatment groups, and there were larger mean increases in parathyroid hormone in dapagliflozin compared with placebo during the cumulative 104-week period (Table 6).

**DISCUSSION**

Dapagliflozin's ability to inhibit renal glucose reabsorption declines with decreasing GFR. Urinary glucose excretion is about 50% lower in patients with T2DM treated with dapagliflozin having CKD stage 3, as compared with patients with normal or mildly impaired renal function.11 Such GFR dependence is expected given the fall in filtered glucose load with worsening CKD stage. Consistent with the lower pharmacodynamic activity, dapagliflozin did not have a significant impact on glycemic control in patients with more advanced CKD, although there was a modest decrease in HbA1c and FPG in patients with a GFR of 45–59 ml/min.

Dapagliflozin showed improvements in weight despite lacking glycemic efficacy. Patients receiving dapagliflozin had modest weight loss in contrast to those receiving placebo, who had small weight gain. The placebo-subtracted weight changes observed here are similar to other studies in patients with normal to mildly impaired renal function,4–9 and the weight loss in this study was similar between patients in CKD stages 3A and 3B. The apparent incongruity in glycemic and weight outcomes may be due to a variety of factors. Patients in this study may have already reached a threshold of glucosuria, beyond which further weight loss was not achieved because of compensatory mechanisms to defend patient each in the dapagliflozin groups and the placebo group, the shift was not reported, and the remaining patients did not exhibit a shift from baseline at week 104.

No change from baseline was noted in mean serum sodium, potassium, bicarbonate, chloride, or calcium with dapagliflozin or placebo. No evidence of hyponatremia or hypokalemia was observed. Marked abnormalities of elevated potassium (≥6 mEq/l) were more common in the placebo group (12.0%) than in dapagliflozin 5-mg (4.8%) or 10-mg groups (4.8%) during the study. More patients experienced marked abnormalities of hyperphosphatemia (≥5.6 mg/dl for patients 17 to 65 years of age or ≥5.1 mg/dl for patients ≥66 years of age) on treatment with dapagliflozin 5 mg (15.7%) or 10 mg (14.3%) than placebo (8.4%). Patients receiving dapagliflozin had a larger mean decrease in serum uric acid than those receiving placebo (Table 6). The mean concentration of serum parathyroid hormone exceeded the upper limit of normal at baseline in all treatment groups, and there were larger mean increases in parathyroid hormone in dapagliflozin compared with placebo during the cumulative 104-week period (Table 6).

**DISCUSSION**

Dapagliflozin's ability to inhibit renal glucose reabsorption declines with decreasing GFR. Urinary glucose excretion is about 50% lower in patients with T2DM treated with dapagliflozin having CKD stage 3, as compared with patients with normal or mildly impaired renal function.11 Such GFR dependence is expected given the fall in filtered glucose load with worsening CKD stage. Consistent with the lower pharmacodynamic activity, dapagliflozin did not have a significant impact on glycemic control in patients with more advanced CKD, although there was a modest decrease in HbA1c and FPG in patients with a GFR of 45–59 ml/min.

Dapagliflozin showed improvements in weight despite lacking glycemic efficacy. Patients receiving dapagliflozin had modest weight loss in contrast to those receiving placebo, who had small weight gain. The placebo-subtracted weight changes observed here are similar to other studies in patients with normal to mildly impaired renal function,4–9 and the weight loss in this study was similar between patients in CKD stages 3A and 3B. The apparent incongruity in glycemic and weight outcomes may be due to a variety of factors. Patients in this study may have already reached a threshold of glucosuria, beyond which further weight loss was not achieved because of compensatory mechanisms to defend patient each in the dapagliflozin groups and the placebo group, the shift was not reported, and the remaining patients did not exhibit a shift from baseline at week 104.

No change from baseline was noted in mean serum sodium, potassium, bicarbonate, chloride, or calcium with dapagliflozin or placebo. No evidence of hyponatremia or hypokalemia was observed. Marked abnormalities of elevated potassium (≥6 mEq/l) were more common in the placebo group (12.0%) than in dapagliflozin 5-mg (4.8%) or 10-mg groups (4.8%) during the study. More patients experienced marked abnormalities of hyperphosphatemia (≥5.6 mg/dl for patients 17 to 65 years of age or ≥5.1 mg/dl for patients ≥66 years of age) on treatment with dapagliflozin 5 mg (15.7%) or 10 mg (14.3%) than placebo (8.4%). Patients receiving dapagliflozin had a larger mean decrease in serum uric acid than those receiving placebo (Table 6). The mean concentration of serum parathyroid hormone exceeded the upper limit of normal at baseline in all treatment groups, and there were larger mean increases in parathyroid hormone in dapagliflozin compared with placebo during the cumulative 104-week period (Table 6).

**DISCUSSION**

Dapagliflozin's ability to inhibit renal glucose reabsorption declines with decreasing GFR. Urinary glucose excretion is about 50% lower in patients with T2DM treated with dapagliflozin having CKD stage 3, as compared with patients with normal or mildly impaired renal function.11 Such GFR dependence is expected given the fall in filtered glucose load with worsening CKD stage. Consistent with the lower pharmacodynamic activity, dapagliflozin did not have a significant impact on glycemic control in patients with more advanced CKD, although there was a modest decrease in HbA1c and FPG in patients with a GFR of 45–59 ml/min.
Table 6 | Summary of laboratory parameters at 104 weeks

|                      | Placebo | Dapagliflozin 5 mg | Dapagliflozin 10 mg |
|----------------------|---------|--------------------|---------------------|
| N                    | 84      | 83                 | 85                  |
| Serum creatinine (mg/dl) |
| Baseline             | 1.46 [0.35] | 1.53 [0.33]       | 1.52 [0.32]         |
| Change at 104 weeks  | 0.09 [0.039] | 0.06 [0.043]      | 0.12 [0.044]        |
| Urinary albumin:creatinine ratio (mg/g) |
| Baseline             | 478 [1193] | 468 [851]         | 401 [785]           |
| Change at 104 weeks  | 69.7 [80.1] | 78.0 [112.5]     | 11.69 [148.6]       |
| Urinary protein:creatinine ratio (mg/mg) |
| Baseline             | 0.75 [1.77] | 0.72 [1.23]      | 0.63 [1.12]         |
| Change at 104 weeks  | 0.09 [0.11] | 0.17 [0.19]      | 0.03 [0.12]         |
| Serum magnesium (mEq/l) |
| Baseline             | 1.72 [0.23] | 1.67 [0.20]      | 1.70 [0.18]         |
| Change at 104 weeks  | -0.06 [0.026] | 0.16 [0.034]    | 0.12 [0.031]        |
| Serum calcium (mg/dl) |
| Baseline             | 9.55 [0.41] | 9.50 [0.49]     | 9.52 [0.42]         |
| Change at 104 weeks  | -0.22 [0.080] | -0.15 [0.089]   | -0.10 [0.067]       |
| Serum phosphorus (mg/dl) |
| Baseline             | 3.84 [0.61] | 3.65 [0.51]     | 3.67 [0.52]         |
| Change at 104 weeks  | -0.13 [0.109] | 0.03 [0.076]    | 0.28 [0.075]        |
| Parathyroid hormone (pg/ml) |
| Baseline             | 66.5 [53.0] | 70.2 [57.4]    | 68.5 [48.9]         |
| Change at 104 weeks  | 3.67 [10.31] | 17.26 [8.84]   | 15.13 [6.22]        |
| Serum uric acid (mg/dl) |
| Baseline             | 7.05 [1.94] | 7.30 [2.12]     | 7.13 [1.71]         |
| Change at 104 weeks  | -0.16 [0.247] | -0.67 [0.254]  | -0.39 [0.204]       |
| Systolic blood pressure (mm Hg) |
| Baseline             | 130.7 [14.1] | 131.8 [17.9]   | 133.7 [17.0]        |
| Change at 104 weeks  | 4.14 [14.07] | -0.25 [18.30]  | -2.51 [16.33]       |
| Diastolic blood pressure (mm Hg) |
| Baseline             | 73.6 [9.29] | 72.5 [9.45]     | 73.8 [9.30]         |
| Change at 104 weeks  | -0.48 [9.60] | -0.55 [11.63]  | -1.27 [9.49]        |

Data are mean (s.d.) at baseline or mean change [s.e.], or (s.d.) for blood pressure, from baseline and include data after rescue.

caloric balance, or this patient population may be more susceptible to weight loss from glucosuria, requiring less glucosuria to drive weight change. Hormones regulating blood glucose (for example, glucagon, insulin, and cortisol) are different from those regulating weight (for example, ghrelin and leptin); therefore, one might expect to see different boundaries for these two outcomes. Further investigation is required to understand the dissociation of glycemic efficacy from weight efficacy seen in this trial. The FPG outcome points to the fact that there is still some glycemic efficacy in this group, although this study is not powered to empirically determine significance. The blood pressure response, which is the cumulative effect of weight loss, natriuresis, and osmotic diuresis, is not expected to be directly dependent on glycemic control, although it is partially dependent on weight change.

Adverse events were balanced among treatment and placebo groups through 104 weeks, except the following: (1) vulvovaginitis and balanitis, and (2) fractures. Genital infection was more frequent with dapagliflozin than with placebo, as has been seen in other studies.4–9 Urinary glucose is thought to explain this increase in infections, serving as a growth substrate for genital fungal pathogens. The significance of the numeric increase in fractures observed with dapagliflozin in this study is uncertain. Many of the fractures were in places not suggestive of bone health issues (for example, toes and patella). The dapagliflozin groups had higher rates of neuropathy and orthostatic hypotension at baseline, conceivably predisposing them to falls. Given the small numbers, the increased fracture incidence could be a chance phenomenon. No increase in fractures was observed in pooled data from patients across the dapagliflozin clinical studies with stage 3A CKD, or in patients with normal to mildly impaired renal function.12,13 In addition, dapagliflozin has been shown to have no effect on bone mineral density or on markers of bone turnover in patients with normal to mildly impaired renal function.14 Although there was no assessment of biomarkers for bone metabolism conducted for this study, the imbalance in fractures raises a safety question specific to patients with advanced (stage 3B or greater) CKD and calls for further study of the issue whether this population is going to be treated with the drug.

Mean eGFR and creatinine clearance fell after 1 week of dapagliflozin treatment, but stabilized thereafter through 104 weeks of therapy, whereas these parameters slowly declined in the placebo group. The initial reduction in eGFR associated with dapagliflozin may be related to a small antihypertensive and diuretic effect, as well as increased tubuloglomerular feedback.15 Importantly, the change in GFR from baseline at week 104 was similar in the dapagliflozin and placebo groups. Patients receiving dapagliflozin were more likely to regress to a lower albumin excretion category than patients receiving placebo. Thus, it will be of great interest to see whether dapagliflozin reduces renal functional loss and worsening of albuminuria.

Dapagliflozin was associated with fewer episodes of, and fewer discontinuations for, hyperkalemia compared with placebo. This protective effect is most likely due to osmotic diuresis induced by dapagliflozin in patients with restricted ability to excrete potassium.

The study has several limitations. The use of insulin-based regimens in almost two-thirds of patients, often with sliding-scale administration, made accurate capture of insulin dosing difficult. Unmeasured differential behavior with respect to sliding scale and other adjustments of insulin between placebo and dapagliflozin could blunt the apparent efficacy
of dapagliflozin. A second limitation is the relatively small size of the study, which was powered for a 0.6% change in HbA1c and therefore limited in its ability to demonstrate smaller glycemic effects. Limited data regarding relevant effect size were available at the time this trial was designed. As we now know from the study of patients with relatively normal kidney function, and the diminished pharmacodynamic effect in patients with decreased renal function, this study may be considered underpowered and subject to type 2 error. Finally, lack of racial diversity in this study could potentially affect its generalizability.

Improvement of glycemic measures with dapagliflozin in this population was not statistically significant because of the inadequate renal function in these patients. The reduced glucose excretion in this population still appears sufficient to account for the weight loss and blood pressure reduction, which are important therapeutic considerations in patients with diabetes and CKD. Apart from the imbalance in fracture, the safety profile of dapagliflozin was similar to that observed in studies involving patients with T2DM and normal renal function to mild renal impairment.

**MATERIALS AND METHODS**

**Trial design**

This multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 2/3 study took place in 111 sites in United States, Argentina, Canada, India, Mexico, Peru, Italy, Australia, France, Spain, Denmark, Puerto Rico, and Singapore. Institutional review boards or independent ethics committees approved this protocol. This study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Each patient provided written informed consent.

Male and female patients aged 18 years old with T2DM and inadequate glycemic control defined as HbA1c ≥ 7.0 and ≤ 11.0% were enrolled from 19 June 2008 to 21 May 2009. Patients had eGFR values of 30 to 59 ml/min per 1.73 m² and body mass index ≤ 45.0 kg/m². Stable antidiabetic regimen was defined as diet and exercise therapy alone or in combination with a regimen of any

---

**Figure 3 | Mean change from baseline after adjustment for baseline value in eGFR for placebo (circles, solid line), dapagliflozin 5-mg (squares, dashed line), and dapagliflozin 10-mg (triangles, dotted line) groups, all plus original pre-enrollment antidiabetic regimen up to 104 weeks including data after rescue.** DAPA, dapagliflozin; eGFR, estimated glomerular filtration rate; PBO, placebo.
24 weeks. The secondary objectives compared the following: (1) change from baseline in FPG and weight for each dose of dapagliflozin vs. placebo at 24 weeks; and (2) change from baseline in eGFR (Modification of Diet in Renal Disease Study equation (four-variable)) and creatinine clearance (Cockcroft and Gault method) for each dapagliflozin dose vs. placebo at 52 weeks.

All safety analyses included data after glycemic rescue. Safety outcomes included serious and nonserious adverse events, discontinuations owing to adverse events, hypoglycemia, laboratory abnormalities, electrocardiograms, and vital signs. Seated blood pressure and heart rate determinations were made in triplicate at each study visit, and supine and standing blood pressure measurements were taken at baseline, and at weeks 1, 12, 24, 52, and 104. Urinary albumin:creatinine ratio and urinary protein:creatinine ratio were based on untimed spot urine sample collections. Patients were actively monitored throughout the trial for clinical signs and symptoms suggestive of urinary tract infection and genital infection, with questioning by the investigator at every visit.

A central laboratory evaluated the assays for the efficacy and safety outcomes, using high-performance liquid chromatography for HbA1c and colorimetric indicator for plasma creatinine and urinary albumin:creatinine ratio.

Statistical analysis
The primary efficacy analysis was based on an analysis of covariance model with treatment group and pre-enrollment antihyperglycemic therapy stratum as fixed effects and the baseline value as a covariate. For patients with no week 24 measurement or rescue before week 24, the last available post-baseline measurement (last observation carried forward) before rescue and before week 24 was used. Treatment-by-baseline interaction and treatment-by-stratification factor interaction were tested at the 0.10 level of significance, and no significant interaction was found. Several sensitivity analyses (completers, longitudinal repeated-measure analysis with or without data after rescue) were performed. Over 104 weeks, longitudinal repeated-measure analysis was used to estimate the change in HbA1c, FPG, and total body weight from baseline; the model included categorical fixed effects of treatment, strata based on pre-enrollment antidiabetic therapy category, week, and treatment-by-week interaction, as well as continuous fixed covariates of baseline measurement and baseline measurement-by-week interaction.

With 80 patients per treatment group, there was at least 88% power to detect a difference of 0.6% in mean change from baseline in HbA1c between each dapagliflozin treatment group and placebo at a significance level of 0.027, using Dunnett’s adjustment and a Bonferroni correction for multiple comparisons. Treatment-by-week interaction and creatinine clearance were not significant at the 0.027 level of significance using Dunnett’s adjustment. The interaction was observed in HbA1c between each dapagliflozin treatment group and placebo.

REFERENCE
1. Tahmasebi AA, Bailey CJ, Del Prato S et al. Management of type 2 diabetes: new and future developments in treatment. Lancet 2011; 378: 182–197.

ACKNOWLEDGMENTS
The study team acknowledges the patients for their participation and commitment during the study. We also thank the investigators and contributors from each study site. We express sincere gratitude to Dr Bruce Leslie for his dedication, involvement, and insights in this study. This Bristol-Myers Squibb and AstraZeneca-supported study is also known as Study MB102029 and is registered with ClinicalTrials.gov, number NCT00663260, available at http://clinicaltrials.gov. Professional medical writing and editorial assistance was provided by Carolyn Carroll, PhD, and Ann L Davis, MPH, employees of Bristol-Myers Squibb. Data from this study were presented at the American Society of Nephrology, Philadelphia, PA, USA, 8–13 November, 2011.

APPENDIX
DEK—consultant for Bristol-Myers Squibb, PF—consultant for Bristol-Myers Squibb and participant in boards for Boehringer Ingelheim, JFL and WT—employees and shareholders of Bristol-Myers Squibb. Principal investigator list: Argentina: Fabio Massari, Alejandra Moisello, Alejandra Oviedo, Silvia Saavedra, Georgina Sposetti, Maria Rosa Ulla, Marisa Vico; Australia: Anne Corbould, Timothy Davis, Greg Fulcher, William Jeffries, Robert Moses, Dennis Yue; Canada: Suzan Abdel-Salam, Ronnie Aronson, Andre Belanger, Patrick Duffy, Jean Garon, Chantal Godin, Ronald Goldenberg, Stuart A Ross, SheldonTobe, Vincent Woo; Denmark: Thure Krapur, Lise Tarnow, Sten Madsbad; France: Beatrice Duly-Bouhanick, Jean-Francois Gautier, Samy Hadjadj, Veronique Kerlan, Michel Marre, Alfred Penformis, Pierre-Jean Saulnier; India: V Balaji, Ganapathi Bantwai, Vaishali Deshmukh, Mala Dharmalingam, Jugal Bihari Gupta, Sunil Jain, Shailaja Kale; Italy: Nicola Carulli, Agostino Consoli, Eleuterio Ferrannini, Paola Fioretti, Francesco Dotta, Carlo Bruno Giorica, Gabriele Perriello, Giuseppe Pugliese; Mexico: Manuel Aguilera, Carlos Cano Ramirez, Jose Ricardo Correa Rotter, Jose Gerardo Gonzalez Gonzalez, Marisol Herrera Marmolejo, Guadalupe Morales, Victor Hugo Olmedo Canchola, Juan Rosas Guzman; Peru: Jose Burga, Jose Caballero, Wilson Gallardo, Luis Zapata; Puerto Rico: Jose L Cangiano, Eugenia Galindo, Luis J Quesada; Singapore: Kok Onn Lee; Spain: Fernando De Alvaro, Sonia Gaztambide, Esteban Poch, Ramon Romero; USA: Intekhab Ahmed, Robert J Anderson, Stephen Aronoff, Akhtar Ashfaq, Richard I Bernstein, Samuel S Blumenthal, D Eric Bolster, Gholamreza Bonabi, James J Brown, Anne M Carrol, Richard S Cherlin, James Cimo, William R Cook, Michael E Campolo, Rajesh Kantilal Desai, Donald Eagerton, Steven Fishbane, Jeremy Flood, John Gerich, Harold H Gillum, Daniel Goodman, Simin Goral, Ronald J Graf, Elizabeth L Helfer, Jennifer Hone, Randall T Huling Jr, Eli Ipp, Rajeev Jain, Eric J Klein, Andrew E Lazar, Joseph JC Lee, Dennis HJ Linden, Howard A Lippes, Norman Martin Lunde, Timothy J Lyons, Zuhayr T Madhun, Samuel O Mayeda, Nicholas J Messina Ill, Jeffrey Lynn Miller, Jesus Ovidio Navarro, Alan E Nolasco, Paul Norwood, John Chip H Reed, III, Daniel B Scheerer, John A Spence, George Tomy, Aaron I Vinik, Peter N Weissman, Thomas Wiegmann.

REFERENCES
1. Tahmasebi AA, Bailey CJ, Del Prato S et al. Management of type 2 diabetes: new and future developments in treatment. Lancet 2011; 378: 182–197.
2. Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): expanded mechanism for D-glucose. J Diabetes 2003; 53: 3–9.
3. Kanai Y, Lee WS, You G et al. The human kidney low affinity Na + -glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994; 93: 397–404.
4. Ferrannini E, Ramos SI, Salsali A et al. Dapagliflozin on glycemic control in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomised, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33: 2217–2224.
5. Bailey CJ, Gross JL, Pieters A et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223–2223.
6. Strojek K, Yoon KH, Hrubu V et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011; 13: 928–938.
7. Nauck MA, Del Prato S, Meier JJ et al. Dapagliflozin vs. glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34: 2015–2022.
8. Rosenstock J, Vico M, Wei L et al. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients...
patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab 2012; 14: 990–999.
15. Thomson SC, Rieg T, Miracle C et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 2012; 302: R75–R83.
16. Kasichayanula S, Liu X, Benito MP et al. The influence of kidney function on dapagliflozin exposure, metabolism, and efficacy in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol 2012; 76: 432–444.
17. Administration FaD. Guidance for industry diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention 2008: Available from. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071624.pdf.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/